Related Experiment Video
Updated: Oct 11, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
The Research Progress in Immunotherapy of Tuberculosis
Jie Mi1, Yan Liang1, Jianqin Liang1
1Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China.
Tuberculosis immunotherapy offers a novel approach to combat drug resistance and toxicity associated with traditional treatments. This strategy aims to regulate the immune response for effective tuberculosis treatment and prevention.
Area of Science:
- Immunology
- Infectious Diseases
- Pharmacology
Background:
- Tuberculosis (TB) remains a global health challenge, necessitating long-term combination antibiotic therapy.
- Current TB treatments face issues of toxicity, poor patient compliance, and emerging drug resistance.
- The immune system's role in Mycobacterium tuberculosis (Mtb) infection progression and outcomes is critical.
Purpose of the Study:
- To review advancements in TB-specific immunotherapy.
- To explore novel therapeutic strategies for TB treatment and prevention.
- To highlight immunotherapy's potential for achieving ultra-short course chemotherapy.
Main Methods:
- Review of current research on TB immunotherapy agents.
- Analysis of immunoreactive substances, therapeutic vaccines, chemical agents, and cellular therapies for TB.
- Examination of immune recognition, response, and regulation in Mtb infection.
Main Results:
- Immunotherapy can modulate the anti-TB immune response.
- Novel agents offer a new avenue for combined TB treatment.
- Potential for improved patient outcomes and prevention in high-risk populations.
Conclusions:
- TB immunotherapy presents a promising alternative and adjunct to conventional treatments.
- Targeting the immune response can overcome limitations of current TB drug regimens.
- Further development of immunotherapy could lead to significantly shorter and more effective TB treatment.
More Related Videos
06:32Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
Related Concept Videos
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Tumor Immunotherapy